Kornimate/medical-research-clean huggingface dataset:
trial of netarsudil for prevention of corticosteroid-induced intraocular pressure elevation

Conditions: Fuchs' Endothelial Dystrophy; Bullous Keratopathy

Summary: cornea transplant recipients who are using topical corticosteroids long-term to prevent transplant rejection will be randomized to use netarsudil or placebo.


Eligibility criteria:
inclusion criteria: * at least 18 years of age; male or female patient undergoing descemet membrane endothelial keratoplasty; patient is able and willing to administer eye drops; patient is able to comprehend and has signed the informed consent form; patient is likely to complete the nine-month course of the study. exclusion criteria: * a patient exhibiting pre-operative intraocular inflammation; a patient with a known sensitivity to any of the ingredients in the study medications; a patient who has a condition (i.e., uncontrolled systemic disease) or is in a situation which in the investigator's opinion may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study; a patient with abnormal eyelid function; a patient that is exhibiting active corneal ulceration, keratitis, or conjunctivitis, or who has a history of herpetic keratitis; a patient who has been diagnosed with uncontrolled glaucoma, prior aqueous shunt or trabeculectomy, or with preoperative intraocular pressure \> 22 mm hg in the potential study eye; presence of any ocular disease that would interfere with the evaluation of the study treatment (however, patients with a history of cystoid macular edema, age-related macular degeneration, corneal neovascularization, and other non-interfering comorbidities may be enrolled); a patient with a history of non-compliance with using prescribed medication; a patient who is concurrently involved in or participated in another randomized clinical trial within 30 days prior to enrollment in this study; patients who are pregnant or planning to become pregnant within the duration of the study.
comparison of two different methods for reducing pain after lung surgery

Conditions: Postoperative Analgesia

Summary: the goal of this clinical study is to compare the effectiveness of the rhomboid intercostal block and sub-servitus plan block and the effectiveness of the rhomboid intercostal block in patients with video-supported thoracoscopic surgery. the main question it aims to answer is: which of these two blocks more effectively reduces the patients' pain?


Eligibility criteria:
inclusion criteria: * patients in american society of anesthesiologists (asa) classes i, ii and iii for whom vats is planned exclusion criteria: * known or suspected local anesthetic allergy * coagulopathy * injection site infection * history of thoracic surgery * serious neurological or psychiatric disorder * severe cardiovascular disease * liver failure * renal failure
ex vivo intra-arterial indigo carmine injection after transanal total mesorectal excision

Conditions: Rectal Neoplasms

Summary: background: an exact lymph node staging is essential in the treatment of rectal cancer. objective: the aim of this study was to assess the effect of indigo carmine injection on the number of retrieved and positive lymph nodes after transanal total mesorectal excision (tatme). design: this is a retrospective, non-randomised study. settings: this study was conducted at a tertiary hospital by a multidisciplinary team. patients: between 2013 and 2019, patients undergoing transanal total mesorectal excision were analysed. patients with indigo carmine injection (intervention group) were compared to those without (control group). interventions: transanal total mesorectal excision was performed with or without ex vivo intra-arterial indigo carmine injection. main outcome measures: the number of retrieved and positive lymph nodes was the primary outcome measure.


Eligibility criteria:
inclusion criteria: * elective, oncologic rectum resection in tatme technique for proven or highly suspected rectal cancer. exclusion criteria: * abdominoperineal resection * extended colon resection * previous surgery of the rectum, the left colon or the mesocolon/-rectum * patients rejecting retrospective data analysis

Keywords: indigo carmine lymph node pathology
direct use of non-centrifuged autologous fat graft

Conditions: Wound Healing Delayed

Summary: there are a limited number of reports related to the direct use of non-centrifuged adipose tissue graft in the literature. this preliminary study aims to present our experience on the efficacy of autologous fat graft use without centrifuging in the treatment of lower extremity wounds.

16 wounds treated with non-centrifuged autologous fat grafts were included in the study. the data were retrospectively analyzed. vac (vacuum-assisted therapy) or silver-impregnated dressing was used to achieve a healthy wound bed before fat grafting. autologous fat grafts were harvested from abdominal or gluteal regions of the patients and injected into the wound bed and wound environment. clinical observation and photograph records were used to follow the wounds.

Eligibility criteria:
inclusion criteria: 1. diabetic, 2. venous 3. traumatic wounds exclusion criteria: 1. malignancy, 2. a life expectation \<1 year, 3. chemical or radiation exposure. 4. pregnancy

Keywords: diabetic food lower extremity fat graft nonentrifuged
comparitive study between uvb alone and uvb with topical tacrolimus 0.03% for the treatment of vitiligo

Conditions: Vitiligo

Summary: vitiligo is a skin disorder that causes substantial social and psychological distress due to multiple patches of depigmentation.disease can target at any age, but it appears to affect various parts of body due to loss of melanin. although the exact cause of the disease is unknown, several theories suggest that genetic predisposition, autoimmunity, and increased vulnerability of melanocytes to the deleterious effects of harmful metabolites all play a role in disease causation. it impacts 0.1%-2% of the general population, with a 30% familial prevalence rate. vitiligo treatment still presents a therapeutic challenge for dermatologists despite a variety of therapeutic modalities. topical steroids, ultraviolet b phototherapy (uvb 280nm-320nm), and photochemotherapy (puva i.e., psoralen plus uva 329nm-400nm) are traditional treatment options. topical calcipotriol and excimer laser are also used. according to research, narrowband uvb (nb-uvb) is effective when used alone. few studies, however also, have reported more than 75% re-pigmentation in patients treated with nb-uvb in conjunction with other modalities. topical immunomodulators (tacrolimus, pimecrolimus) are considered safe and effective long-term treatments for vitiligo because they do not cause skin atrophy, which is associated with long-term use of topical corticosteroids. tacrolimus is an effective treatment for vitiligo when used alone; in one study, 61% of patients showed more than 75% repigmentation when treated with tacrolimus alone. another study found that when tacrolimus was combined with nb-uvb, 73% of patients experienced more than 50% repigmentation. the objective of this research was to present a comparatively new mode of treatment that may be beneficial to vitiligo patients.


Eligibility criteria:
inclusion criteria: * patients having 20-60 years of age * non pregnant * no history of photosensitivity * no history of immunosuppression or immunosuppressive drugs * no histry of steroids use oral or topical in last four weeks exclusion criteria: * pregnancy * lactation * history of photosensitivity * photo-aggravated dermatoses * history of any immunosuppressive disorder or use of immunosuppressive medicine * history of using steroids either oral or injectable within the previous one month * history of skin malignancy

Keywords: phototherapy tacrolimus vitiligo
study for atrial fibrillation reduction (safari)

Conditions: Atrial Fibrillation, Bradycardia

Summary: atrial fibrillation (af), which is the name for rapid beats in the upper chambers of the heart, is the world's most common kind of irregular heart beat. people with af experience symptoms such as heart palpitations (a racing or pounding feeling in the chest), shortness of breath, dizziness, fatigue or weakness. although af can occur in otherwise healthy people for no apparent reason, it is sometimes associated with high blood pressure, heart disease or lung problems. the purpose of the safari trial is to study the effectiveness of pacing algorithms in the upper chamber of the heart for patients who have both af and bradycardia (slow heart beat).


Eligibility criteria:
inclusion criteria: * subjects with a slow heartbeat who are in need of dual chamber pacing (pacing in both the atrium and ventricle). * subjects who have experienced at least two episodes of rapid heart beats three months prior to enrollment. exclusion criteria: * subjects who have a history of permanent (chronic) or persistent (non self-terminating) atrial fibrillation. * subjects with atrial fibrillation due to reversible cause, (e.g. thyroid disease, pericarditis, post-surgery, alcohol abuse). * subjects with a history of one or more cardioversions (changing an abnormal heart rhythm into a normal one by either using medication or by the application of an electric shock) six months prior to enrollment.

Keywords: pacemaker, atrial fibrillation/therapy
evaluating the pharmacokinetic interaction between ad-2011 and ad-2012

Conditions: Hyperlipidemias; Hypertension

Summary: the purpose of this study is to evaluate the pharmacokinetic interaction between ad-2011 and ad-2012 in healthy male volunteers.

to evaluate the pharmacokinetic interaction, safety and tolerability of the combination compared with the single administration of ad-2011 and ad-2012.

Eligibility criteria:
inclusion criteria: * healthy male between 19 and 50 years of age at the time of screening * weight between 50 kg and 90 kg and body mass index (bmi) between 18.0 kg/m2 and 27.0 kg/m2 exclusion criteria: * clinically significant disease or history of clinically significant disease such as liver, kidney, nervous system, respiratory, endocrine\*hematologic, cardiovascular, urinary, psychiatric * gastrointestinal problem or history of gastrointestinal problem and history of gastrointestinal surgery * ast, alt values over than 1.5 times of uln at screening * hdl values less than 35 mg/dl * a person who has a history of drug abuse or who has positive result for an abuse drug in a urine screening test
satavaptan in the prevention of ascites recurrence in patients with ascites due to cirrhosis of the liver

Conditions: Ascites; Liver Cirrhosis

Summary: primary to evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. secondary to evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in participants with cirrhosis of the liver and recurrent ascites. the one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (pasccal-2).


Eligibility criteria:
inclusion criteria: * participants with cirrhosis of the liver. * participants with recurrent ascites having undergone both of the following: * therapeutic paracentesis for the removal of ascites in the previous 24 hours with the removal of \> 4 litres of fluid. * at least one other therapeutic paracentesis in the previous 3 months. exclusion criteria: * participants with an existing functional transjugular intrahepatic portosystemic shunt (tips) or other shunt. * known hepatocellular carcinoma. * participants with ascites of cardiac origin or due to peritoneal infection (e.g. tuberculosis) or peritoneal carcinoma. * participants previously exposed to satavaptan in the past 12 months.
neuropsychomotor functions in children with autism spectrum disorder

Conditions: Autism Spectrum Disorder

Summary: the aim of the study is to describe the feasibility of the passation of the assessment battery of psychomotor functions tests (np-mot) in children aged 4 to 11 years with a diagnosis of autism spectrum disorder: number and type of evaluable events, number and type of tests with a deficit compared to the standard results.

after informed consent obtention, the children will be submitted to the different tests of the battery to evaluate the psychomotor functions. the results will be compared with other data collected from the routine practise : socio-demographic data, medical and developmental antecedents,psychological tests (kabc ii, rey test, london tower test, ...), psychomotor evaluation (mabc, evaluation of manual praxis, visual abilities, frostig test), understanding data (n-eel test), neuropediatric examination, clinical assessment (adi-r, cars). the use of this battery allows this fine discriminative assessment of the psychomotor functions involved in the movement. exploring each function will allow to take into account qualitative and quantitative aspects of the movement in every aspects, and this is not applied in the routine care until now. calibration for each event can explore each function independently of each other, and will provide information to determine any specific developmental characteristics improve care.

Eligibility criteria:
inclusion criteria: * informed consent from the parents or the legal representative * age 4 to 11 * autism spectrum disorder diagnosis according to the diagnostic and statistical manual of mental disorders, fourth edition- text revised exclusion criteria: * bad understanding of the french language * motor disability from lesion or accidental origin, proved genetic or neurologic disease * deafness, blindness * parents with administrative or judiciary protection, and without health insurance

Keywords: autism spectrum disorder neuropsychomotor assessment np-mot motor skills gross motor
user testing of an end of life medication support intervention for lay carers (palliate).

Conditions: End of Life; Support, Family

Summary: the aim of this study is to evaluate the acceptability, safety and efficiency of the palliate intervention. the palliate intervention is a nurse-led process that includes training and documentation materials to support lay carers in administering top up medications to loved ones at the end of life at home. the palliate intervention was designed based on the cariad\* intervention using user testing and has been successfully piloted and rolled out in central and north west london national health service (nhs) foundation trust. \*carer-administration of as-needed sub-cutaneous medication for breakthrough symptoms in homebased dying patients.


Eligibility criteria:
inclusion criteria: * individuals aged 18 years or older and able to communicate in english. exclusion criteria: * individuals aged less than 18 years old and/or unable to communicate in english.

Keywords: palliative care
inhaled furosemide versus placebo for acute viral bronchiolitis in hospitalized infants

Conditions: Bronchiolitis

Summary: we hypothesize that inhaled furosemide will be an effective treatment in infants with acute bronchiolitis.


Eligibility criteria:
inclusion criteria: * age: 0-12 months. * infants who are otherwise healthy * infants with chronic lung disease of prematurity (bpd) will be included, but will be analyzed separately. * parents signed a written informed consent. exclusion criteria: * • other previous or co-morbidity, specifically: respiratory (other than bpd, like asthma or cystic fibrosis), cardiac or renal disease or anomaly.
fracture healing assessed by hr-pqct after administration of calcium and vitamin d

Conditions: Bone Fracture

Summary: this study is designed as a single-blind rct in 80 postmenopausal women to compare the effect of immediate administration of daily calcium supplementation (1000 mg calcium) or two daily dosages of calcium + vitamin d (1000 mg calcium + 880 iu vitamin d or 1000 mg calcium + 1760 iu vitamin d) to standard care (administration of vitamin d3 12 weeks after fracture) in terms of calculated bone strength based on analysis of cortical and trabecular bone parameters using hr-pqct, fracture healing and functional outcome.


Eligibility criteria:
inclusion criteria: * postmenopausal women older than 50 years who present themselves in clinic with a distal radius fracture due to a trauma. * patients with a stable distal radius fracture treated by cast immobilization. * patients who understand the conditions of the study and are willing and able to comply with the scheduled biochemical and radiographic evaluations and the prescribed rehabilitation. * patients who signed the ethics committee approved specific informed consent form prior to inclusion. exclusion criteria: * patients who underwent surgery of the wrist or radius on a previous occasion on the same side or who need surgery this time. * patients with active or suspected infection such as pneumonia or complicated urinary tract infection in the last 3 months. * patients with malignancy or a pathological fracture in the last 12 months. * patients with a neuromuscular or neurosensory deficit, e.g. parkinson's disease, which would limit the ability to assess the performance during the healing period. * patients with known systemic or metabolic disorders leading to progressive bone deterioration, such as: hyperthyroidism, hyperparathyroidism, chronic kidney disease with egfr\<30 ml/min, sarcoidosis, hypercalcemia, * patients with an active inflammatory disease during the last year such as rheumatoid arthritis, systemic lupus erythematous, inflammatory bowel disease, e.g. crohn's disease and ulcerative colitis. * the use of glucocorticoids during the last 12 months. * patients with an allergy to calcium, calcium carbonate, cholecalciferol, aspartame, citric-acid, lactose, dimethicone, methylcellulose, sorbic acid, macrogole, polyvidone, mannitol, orange flavour, natriumsaccharine, starch or sucrose. * patients, who as judged by the principal investigator, are mentally incompetent or are unlikely to be compliant with the follow-up evaluation schedule. * patients with other severe concurrent joint involvements that can affect their outcome. * patients who are already selected for another trial concerning distal radius fractures.

Keywords: fracture healing calcium supplementation vitamin d supplementation hr-pqct
transcranial photobiomodulation for executive function in bipolar disorder

Conditions: Bipolar Disorder

Summary: transcranial light therapy, or transcranial photobiomodulation (tpbm), is a treatment that stimulates the brain by applying near-infrared light to the forehead. transcranial light therapy has been found to promote brain metabolism, which may help improve executive function in people with bipolar disorder. the research team proposes a novel approach to treating bipolar disorder by using transcranial light therapy.

this study involves a virtual screening visit, 7 in-office visits, and a virtual check-in call with a clinician. participation will last approximately 3 weeks in total. participants will attend a baseline visit during which they will complete mood questionnaires and a gambling task. participants will then receive five treatments of transcranial light therapy over one week. the first and last of these treatments will be administered while the participant is in an mri scanner. at the first visit, participants will also receive a "sham" tpbm treatment, meaning that the device will simulate real treatment, but will not actually apply the near-infrared light. the check-in call will occur approximately 2-3 days after the final treatment visit. this will be a brief call with a study clinician to check-in on the participant's mental and physical health. the follow up visit will occur approximately one week after the final visit. subjects will be asked to complete mood questionnaires and/or gambling tasks during the first and fifth treatment visits, as well as at the follow up visit.

Eligibility criteria:
inclusion criteria: * adults between the ages of 18 and 65 * diagnosis of bipolar disorder * currently experiencing symptoms of impulsivity * vision normal or corrected to normal with contacts exclusion criteria: * currently in depressive, manic, or mixed episode * currently psychotic * judged to be at serious and imminent suicidal risk * currently in alcohol or substance use disorder (meeting criteria in the past 3 months) * unstable medical conditions * inability to consent or to complete study procedures * failure to meet standard mri safety requirements (e.g. claustrophobia, non-removable piercings, implanted medical devices, other non-removable metals) * changes in medications or use of augmentative devices and other interventions in the 2 weeks prior to the study * participation in other clinical research trials that may influence primary outcomes or adherence to the proposed study * current pregnancy.

Keywords: bipolar bipolar disorder
correlation study between socio-economical deprivation and oral health in children of 9 years of age

Conditions: Tooth Decay; Missing Tooth/Teeth

Summary: retrospective, observational cohort study. objectives : to search for correlations between socio-economical deprivation and oral health in french children of 9 years of age. to study the annual use of oral and dental care of children from 6 to 9 years of age depending on their geographical and socio-economical environment, and the medical demography ; to identify and study the share of the cohort not using oral and dental care, and the socio-economical and geographical factors implicated in this non-use of care. the study will use data from the french nationwide healthcare systems database (snds) and data from the french national institute of statistics and economic studies (insee).


Eligibility criteria:
inclusion criteria: * being born in 2008 * being covered by the mandatory french national health insurance plan without discontinuity between 2014 and 2017 * living in france without discontinuity between 2014 and 2017 exclusion criteria: - none

Keywords: oral health odontology epidemiology public health deprivation
reproducibility of hba1c measurement on the aina hba1c monitoring system

Conditions: Diabetes

Summary: a three site study to evaluate the reproducibility of the aina hba1c monitoring system in quantitative determination of glycosylated hemoglobin (hba1c) took place at the following sites: 1. forsyth institute in cambridge, ma 2. orange county research center in tustin, ca 3. activmed practices \& research in methuen, ma

each site tested three identical samples of hba1c, at three different levels of hba1c measurement. samples were drawn at the forsyth institute, received and blinded by the sponsor, and returned to forsyth institute for testing. samples were tested in triplicate, twice per day, over the course of five days, by three trained operators.

Eligibility criteria:
inclusion criteria: * agree to the terms of this consent form * sign this consent form * be 18 years or older * have an hba1c measured by a reference method within the last three months or based on medical history that is expected to fall in the range of 4 to 15% * provide blood samples from your arm and finger * come in in the morning of the study visit exclusion criteria: * not have a recent history of anemia or hemoglobin concentration above 20% * not be pregnant * not have previously given a blood sample to the study sponsor for a study

Keywords: hba1c